English
Specials
    Upgrade

    Moneycontrol

    Budget 2023Budget 2023
    Upcoming Event : LeapToUnicorn - mentoring, networking and fundraising for startups. Register now
    you are here: HomeNewsBusinessMoneycontrol Research

    Sun Pharma: Sustained traction in speciality to be a re-rating driver

    Sun Pharma's India business is expected to gain traction as sub-chronic and acute therapies pick up with the opening up of clinics/OPDs. This is likely to be fully backed by the field force where the expansion has recently been completed

    Anubhav Sahu
    January 31, 2021 / 01:22 PM IST
    Sun Pharma: Sustained traction in speciality to be a re-rating driver

    Revlimid is a blockbuster blood cancer drug with sales of $12.1 billion for BMS in 2020.

    PRO Only Highlights
    -      Quarterly performance largely backed by improved realisations
    -      Medium-term triggers China plus and protectionist measures for tyre industry
    -      Valuations not inexpensive; but improved medium-term outlook

    Highlights - Q3 sales helped by US and India businesses - Improved margins mainly because of lower operating expenses and product mix - Few speciality products likely to break-even next fiscal - Heavy product launch pipeline to support India business India’s largest pharma company Sun Pharma (CMP: Rs 586 Market cap: Rs 140,649 crore) has posted two back to back strong quarters driven by speciality products. With the economy recovering, traction for even the US generic business has been better than expected and there has been market share...

    • PRO Panorama

      Moneycontrol Pro Panorama | Autos on the road to recovery

      Jan 25, 2023 / 03:44 PM IST

      In today’s edition of Moneycontrol Pro Panorama: Gland Pharma’s poor streak cause for concern, no signs of recovery for Colgat...

      Read Now
    • PRO Weekender

      Moneycontrol Pro Weekender: The downsizing of Davos Man

      Jan 21, 2023 / 10:10 AM IST

      The World Economic Forum has been desperately trying to reinvent itself, but Davos Man’s heydays are a thing of the past

      Read Now

    To read the full story, Subscribe to Moneycontrol PRO

    Access the exclusive stories, weekly investment ideas and daily technical calls in an Ad free experience

    View Plans

    Already a member? Sign in

    Limited Period offer on Moneycontrol PRO. Subscribe to PRO and get up to

    50% OFF

    What Do You Get

    • Ad free experience

      Experience a non-intrusive navigation and faster response in the ad free mode

    • Sharpest Opinions

      Access to 230+ exclusive stories per month from our editorial and Experts

    • +

      Have a Global edge with access to content from world renowned experts and journalist

    • Actionable Insights

      Access to 40+ weekly investment ideas including 4 daily technical calls

    • Virtual Events

      Exclusive access to live webinars from market experts on trading and investment strategies

    • Newsletters

      Daily and weekly insights bundled and sent to your inbox to keep you ahead in the race.

    View Offers

    Get upto 50% discount on limited period offers